Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 17Terminated 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 13Lymphoid 4Thoracic 2Sarcoma 2Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Thalidomide × Genitourinary × Clear all
NCT00090870 2018-07-12

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

Medical University of South Carolina

Phase 2 Terminated
10 enrolled 4 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00450008 2016-03-17

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Terminated
9 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡